Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is an orally administered, direct-acting, reversible P2Y12 receptor antagonist. It is used to prevent thrombotic events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* Prevention of thrombotic events (e.g., cardiovascular death, MI, stroke) in patients with acute coronary syndrome (ACS).
* Prevention of thrombotic events in patients with a history of MI (≥1 year prior) and high risk for an aterothrombotic event.
## Adult Dosing
* **Acute Coronary Syndrome (ACS):**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or until invasive procedures are completed. A dose of 60 mg orally twice daily may be considered for long-term maintenance therapy beyond 12 months in select patients based on individual risk assessment.
* **History of Myocardial Infarction (≥1 year prior) and High Risk:**
* **Maintenance Dose:** 60 mg orally twice daily.
## Pediatric Dosing
* Ticagrelor is not recommended for use in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is required for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is required for mild to moderate renal impairment. Data is limited for severe renal impairment.
## Contraindications
* Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
* Known history of intracranial hemorrhage.
* Hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Common:** Bleeding (major and minor), dyspnea, bradycardia.
* **Serious:** Life-threatening bleeding, ventricular pauses.
* **Other:** Hypotension, cough, rash, hyperkalemia.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor levels; strong inducers (e.g., rifampin, phenytoin) can decrease levels.
* **P-glycoprotein (P-gp) Inhibitors:** Strong P-gp inhibitors (e.g., cyclosporine) can increase ticagrelor levels.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Concurrent use with aspirin is generally recommended for ACS, but caution and consideration of bleeding risk are necessary with other agents.
* **Simvastatin/Lovastatin:** Ticagrelor can increase the plasma concentrations of simvastatin and lovastatin (CYP3A4 substrates). Avoid doses of simvastatin >40 mg and lovastatin >20 mg.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Heart Rate:** Monitor for bradycardia, especially in patients with risk factors.
* **Electrolytes:** Monitor potassium levels, particularly in patients with risk factors for hyperkalemia.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning its effect can be more readily reversed compared to clopidogrel or prasugrel, which can be important if urgent surgery is required.
* Dyspnea is a common side effect and is typically mild and transient. If severe or persistent, further evaluation is warranted.
* The 90 mg twice daily dose is standard for ACS for at least 12 months. The 60 mg twice daily dose is approved for long-term maintenance after 1 year in ACS, and for patients with prior MI and high risk.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant guidelines for complete details and to verify dosing and safety information before making any clinical decisions.
